[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 464
Citations 0
Comment & Response
November 26, 2014

Costs of New Treatments for Hepatitis C Infection—Reply

Author Affiliations
  • 1CVS Caremark, Woonsocket, Rhode Island
  • 2CVS Caremark, Cumberland, Rhode Island
JAMA. 2014;312(20):2168-2169. doi:10.1001/jama.2014.14352

In Reply Dr Lopert and Mr Welch and Dr Green make the point that the Gilead purchase of Pharmasset does not accurately reflect the true costs of development of sofosbuvir. We agree.

Our point was simply that the $11 billion price was the most that one could say that it cost Gilead to bring sofosbuvir to market, and even then their return on investment is extraordinary.

In addition, Lopert and Welch call for a formal cost-effectiveness analysis. We agree and are currently undertaking that research.

First Page Preview View Large
First page PDF preview
First page PDF preview
×